Tubulis closed a major Series C financing (reported in euros) to accelerate clinical development of its next‑generation antibody‑drug conjugates (ADCs). The round—among the largest European biotech raises this year—will bankroll expansion of TUB‑040 into additional tumor types and earlier lines of therapy and to advance the company’s in‑house ADC engineering platform. Company statements and reporting indicate the cash positions Tubulis to present and expand clinical datasets at upcoming oncology meetings and to scale manufacturing and translational work. Investors cited include leading life‑science funds; BioCentury and STAT provided market analysis of the round and its strategic implications for ADC competition.